A new study suggests that measuring apolipoprotein B (apoB) may be a better way to identify people at high risk of heart disease than relying on standard LDL (“bad”) cholesterol alone. ApoB measures the number of harmful cholesterol-carrying particles in the blood, providing a more accurate picture of cardiovascular risk. Researchers found that using apoB to guide treatment decisions could prevent more heart attacks and strokes while remaining cost-effective for the healthcare system. Although current guidelines still primarily use LDL cholesterol, these findings support a growing role for apoB testing in helping doctors personalize treatment and improve heart disease prevention.
Read more at ScienceDaily